Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Randomized Phase II Trial Evaluates Ociperlimab Plus Tislelizumab and BAT1706 in Advanced Hepatocellular Carcinoma
Adding a new drug did not help liver cancer patients survive longer
This randomized phase II trial enrolled 94 patients with advanced hepatocellular carcinoma.
A new drug combination showed promise for advanced liver cancer, but adding a third drug did not improve results.
Cadonilimab plus chemotherapy shows 72.5% ORR in 51 patients with cervical cancer
New Cervical Cancer Drug Shrinks Tumors In Early Real World Tests
This prospective observational cohort study enrolled 51 patients with cervical cancer receiving cadonilimab (≥2 cycles) with chemotherapy, w…
A new cervical cancer drug shows promising results in early real-world tests, shrinking tumors for most patients while keeping side effects …
Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
Can You Take Blood Thinners With Cancer Drugs Safely?
This retrospective analysis at Hunan Cancer Hospital assessed 208 patients receiving concurrent anti-VEGF agents and anticoagulants for VTE.
New research suggests it is generally safe to use blood thinners with certain cancer treatments.
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients
Surgery Doesn’t Extend Life for Advanced Colon Cancer
This randomized clinical trial enrolled 382 adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlan…
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
Pembrolizumab Plus Paclitaxel Improves Survival in Recurrent Ovarian Carcinoma Compared to Paclitaxel Alone
New Drug Combo Extends Survival for Tough Ovarian Cancer
This randomised, double-blind phase 3 study evaluated pembrolizumab plus paclitaxel versus placebo plus paclitaxel in 643 female participant…
This new combination offers a meaningful survival boost for women with recurrent ovarian cancer that has become resistant to standard treatm…
Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement
A rare cancer found in the uterus and ovaries may be treated with surgery and chemo for over five years
This case report describes a 45-year-old woman with signet-ring cell carcinoma of the appendix involving the uterus and ovaries.
A rare cancer starting in the appendix showed up in the uterus and ovaries. Treatment with surgery and drugs helped a woman survive past fiv…